The present disclosure is related to apparatus and methods which may be used to support an intraosseous device after insertion into a target area and/or to communicate fluids with the target area via the intraosseous device.
Vascular access is often essential to viability of a patient in emergency situations, during transportation to a medical facility and during treatment at the medical facility. Obtaining vascular access may be a significant problem in five to ten percent of patients of all ages and weight in pre-hospital and hospital environments. This equates to approximately six (6) million patients in the U.S. annually. For example patients suffering from conditions such as shock, cardiac arrest, drug overdose, dehydration, diabetic coma, renal failure and altered states of consciousness may have very few (if any) accessible veins.
In a hospital or similar medical facility, central line access is often an alternative to IV access. However, central line access generally takes longer, costs more, may have a higher risk of complications and requires skilled personnel to properly insert the central line. In many hospital environments, nurses and physicians are increasingly turning to intraosseous (IO) access as an alternative to IV access, rather than central lines. In pre-hospital environments, paramedics and other emergency medical service (EMS) providers are often finding that IO access may be quick, safe and effective when IV placement is challenging.
Intraosseous (IO) access to bone and associated bone marrow has been used for other procedures including, but not limited to, obtaining biopsy specimens for analysis and research and also for bone marrow transplantation and/or stem cell research.
In accordance with teachings of the present disclosure, apparatus and methods may be provided to facilitate access to a patient's vascular system and to communicate fluids with the vascular system. Intraosseous (IO) devices and techniques incorporating teachings of the present disclosure may communicate various fluids including, but not limited to, drugs and medication with the vascular system. Supporting structures, attachment devices and attachment techniques incorporating teachings of the present disclosure may be used to enhance performance of various types of IO devices including, but not limited to, IO devices used to communicate fluids with the vascular system and/or IO devices used to obtain bone and/or bone marrow samples.
One aspect of the present disclosure may include providing apparatus and methods for stabilizing or securing an intraosseous device disposed in a bone and associated bone marrow. Supporting structures, attachment devices and attachment techniques incorporating teachings of the present disclosure may be used with a wide variety of intraosseous devices.
The present disclosure may provide apparatus and methods to establish vascular access during treatment at a wide variety of acute and chronic conditions at locations and facilities including, but not limited to, accident sites, emergency rooms, battlefields, emergency medical services (EMS) facilities, oncology treatment centers, and chronic disease treatment facilities. Various teachings of the present disclosure may be used during treatment of animals in a veterinary practice.
A more complete and thorough understanding of the present embodiments and advantages thereof may be acquired by referring to the following description taken in conjunction with the accompanying drawings, in which like reference numbers indicate like features, and wherein:
Preferred embodiments of the disclosure and its advantages are best understood by reference to
Vascular system access may be essential for treatment of many serious diseases, chronic conditions and acute emergency situations. Yet, many patients experience extreme difficulty obtaining effective treatment because of inability to obtain or maintain intravenous (IV) access. An intraosseous (IO) space provides a direct conduit to a patent's vascular system and systemic circulation. Therefore, IO access is an effective route to administer a wide variety of drugs, other medications and fluids. Rapid IO access offers great promise for almost any serious emergency that requires vascular access to administer life saving drugs, other medications and/or fluids when traditional IV access is difficult or impossible.
The upper tibia proximate a patient's knee or the humeral head proximate a patient's shoulder may be used as insertion sites for an IO device to establish access with the patient's vascular system. Sternal access (not expressly shown) may also be used as an insertion site. Availability of multiple intraosseous sites has proven to be especially important in applications such as emergency treatment of battlefield casualties or other mass casualty situation. Teachings of the present disclosure may be used at a wide variety of insertion sites.
The humeral head and sternum provide insertion sites for an intraosseous device located above the diaphragm of a patient. Placing or inserting an intraosseous device above the diaphragm may be preferred by some emergency room physicians and trauma surgeons for rapid vascular access.
Teachings of the present disclosure may be satisfactorily used to place or insert an intraosseous device and to communicate fluids with the intraosseous device at a wide variety of locations. Teachings of the present disclosure are not limited to IO devices which may only be inserted at the tibia, humerus, or sternum.
Intraosseous access may also be used as a “routine” procedure with chronic conditions which substantially reduce or eliminate the availability of conventional IV sites. Examples of such chronic conditions may include, but are not limited to, dialysis patients, seriously ill patients in intensive care units and epilepsy patients. Intraosseous devices along with supporting structure and/or monitoring equipment incorporating teachings of the present disclosure may be quickly and safely used to provide IO access to a patient's vascular system in difficult cases such as status epilepticus to give medical personnel an opportunity to administer crucial medications and/or fluids. Further examples of such acute and chronic conditions are listed near the end of this written description.
The ability to satisfactorily maintain an intraosseous (IO) device such as an IO needle at a desired insertion site may be problematic when a patient is moving or has the potential to move. Inserting an IO device in the wrong place may expose a patient to potential harm. Patient movement may be of special concern for patients suffering from status epilepticus or violent patients (drug overdoses or mental status changes) that need to be controlled for their safety and treatment. Epileptic patients may shake violently for prolonged periods which makes starting a conventional IV nearly impossible.
Insertion sites and associated target areas for IO placement such as a patient's tibia, humerus, or sternum are often larger than insertion sites and associated target areas for placement of an IV device making IO insertion easier than IV insertion. Problems with maintaining an IO device may be minimized by using supporting structures along with attachment mechanisms and attachment techniques incorporating teachings of the present disclosure. Such supporting structures, attachment mechanisms and attachment techniques may be easy to apply, even in difficult field environments.
Supporting structures, attachment mechanisms and attachment techniques may also be used when harvesting bone and/or bone marrow samples using an intraosseous device. Such supporting structures, attachment mechanisms and attendant techniques may be particularly useful when an IO device is inserted into a patient's humeral head or sternum (not expressly shown) or when inserted into small or pediatric patients. Such supporting structures, attachment mechanisms, and/or attachment techniques may substantially reduce and/or eliminate wobble which may occur during manipulation of an intraosseous device during treatment to obtain one or more samples at a respective insertion site. In addition, such attachment mechanisms and techniques may substantially reduce and/or eliminate the chance of dislodging the IO device in the event of patient movement or inadvertent contact by other persons.
The term “driver” may be used in this application to include any type of powered driver or manual driver satisfactory for installing an intraosseous (IO) device such as a penetrator assembly or an IO needle into a selected target site.
For some applications a powered driver or a manual driver may be directly coupled with an IO device. For other applications various types of connectors may be used to couple a manual driver or a powered driver with an IO device. A wide variety of connectors and associated connector receptacles, fittings and/or other types of connections with various dimensions and configurations may be satisfactorily used to releasably engage an IO device with a powered driver or a manual driver.
The term “intraosseous (IO) device” may be used in this application to include any hollow needle, hollow drill bit, penetrator assembly, bone penetrator, catheter, cannula, trocar, inner penetrator, outer penetrator, IO needle or IO needle set operable to provide access to an intraosseous space or interior portions of a bone. A wide variety of trocars, spindles and/or shafts may be disposed within a cannula during installation at a selected target area. Such trocars, spindles and shafts may also be characterized as inner penetrators. A cannula may be characterized as an outer penetrator.
The term “fluid” may be used within this patent application to include any liquid including, but not limited to, blood, water, saline solutions, IV solutions, plasma or any mixture of liquids, particulate matter, dissolved medication and/or drugs appropriate for injection into bone marrow or other target sites. The term “fluid” may also be used within this patent application to include body fluids such as, but not limited to, blood, bone marrow and cells which may be withdrawn from a target site.
Various features of the present disclosure may be described with respect to powered driver 10 and/or manual driver 10a. Various features of the present disclosure may also be described with respect to intraosseous device-hub 60. However, supporting structures, attachment mechanisms and attachment techniques incorporating teachings of the present disclosure may be satisfactorily used with a wide variety of drivers and intraosseous devices. The present disclosure is not limited to use with intraosseous device-hub 60 or drivers 10 or 10a.
For some applications pin type fitting or connector 20 may be formed on the one end of the rotatable shaft. A matching box type fitting or connector receptacle may be provided on an intraosseous device so that connector 20 of powered driver 10 may be releasably engaged with the intraosseous device. For some applications, connector 20 may have a pentagonal shaped cross section with tapered surfaces formed on the exterior thereof.
Handle 16 may include a battery (not expressly shown) or other power source. Handle 16 may also include trigger assembly 17 for use in activating powered driver 10. Examples of powered drivers are shown in pending patent application Ser. No. 10/449,503 filed May 30, 2003 entitled “Apparatus and Method to Provide Emergency Access to Bone Marrow,” now U.S. Pat. No. 7,670,328; Ser. No. 10/449,476 filed May 30, 2003 entitled “Apparatus and Method to Access Bone Marrow,” now U.S. Pat. No. 7,699,850; and Ser. No. 11/042,912 filed Jan. 25, 2005 entitled “Manual Intraosseous Device,” now U.S. Pat. No. 8,641,715.
Connector 20a may extend from first end 14a of handle 16a. Connector 20a may have a configuration and dimensions similar to previously described connector 20.
However, manual drivers may be provided with a wide variety of connectors and/or connector receptacles. Various details concerning manual drivers are discussed in more detail in pending U.S. patent application, Ser. No. 11/042,912 filed Jan. 25, 2005, entitled “Manual Intraosseous Device,” now U.S. Pat. No. 8,641,715.
First end 31 may include opening 34 formed with various configurations and/or dimensions. For some applications opening 34 may be sized to receive portions of a drive shaft. One or more webs (not expressly shown) may also be formed in first end 31 extending from opening 34. Open segments or void spaces (not expressly shown) may be formed between such webs. Opening 34 and associated webs (if any) may be used to releasably engage connector 30 with either a manual driver or a powered driver.
The configuration and dimensions of opening 34 may be selected to be compatible with releasably engaging connector 30 of needle set 40 with connector 20 of powered driver 10 or connector 20a of manual driver 10a. For some applications metallic disk 35 may be disposed within opening 34 for use in releasably engaging needle set 40 with a magnet (not expressly shown) disposed on the end of connector 20 or 20a.
For some applications exterior portion of connector 30 may include an enlarged tapered portion adjacent to first end 31. A plurality of longitudinal ridges 33 may also be formed on the exterior of connector 30 proximate first end 31. The enlarged tapered portion and/or longitudinal ridges 33 may allow an operator to grasp associated needle set 40 during attachment with a driver and may facilitate disengagement of connector 30 from hub 60 after outer penetrator or cannula 70 has been inserted into a bone and associated bone marrow.
Second opening 36 may be formed in second end 32 of connector 30. For example threads 37 may be formed on interior portions of opening 36 extending from second end 32. Threads 37 may be sized to engage threads 67 formed on an exterior portion of hub 60. In addition, opening 36 may include male luer slip 38, configured to correspond to female luer slip 68 in hub 60. It should be noted that male luer slip 38 and female luer slip 68 do not come into physical contact when connector 30 and hub 60 are connected. Threads 37 and 67 may be characterized as forming portions of a Luer lock connection. However, the present disclosure is not limited to threads 37 and 67. Various types of releasable connections including, but not limited to, other types of locking connections may be formed on adjacent portions of connector 30 and hub 60.
Trocar or inner penetrator 42 may be securely engaged with connector 30 extending from second end 32. The dimensions and configuration of inner penetrator 42 may be selected to allow inner penetrator 42 to be slidably inserted into longitudinal bore 73 of outer penetrator or cannula 70. Trocar 42 may include first end or tip 44. The dimensions and configuration of tip 44 may be selected to accommodate inserting penetrator assembly 40 into bone and associated bone marrow at a selected target area in a patient.
Hub 60 may include first end or distal end 61 and second end or proximal end 62. First end 61 of hub 60 may have a generally cylindrical pin-type configuration compatible with releasably engaging hub 60 with second end 32 of connector 30. As previously noted, threads 67 formed adjacent to first end 61 of hub 60 may be releasably engaged with threads 37 formed on interior portions of opening 36 of connector 30.
For some applications first end 61 of hub 60 may be configured to accommodate various connectors and/or to allow access for various methods of fluid delivery (e.g., a luer lock, a syringe, a standard IV connection and/or a needle). For example, first end 61 of hub 60 may include a check valve (not expressly shown), the check valve operable to allow fluid access via engaged luer lock connections and to restrict fluid access in the absence of an engaged luer lock connector. In another example, first end 61 of hub 60 may include a gasket (not expressly shown) operable to allow fluid access when punctured by a needle and to restrict fluid access in the absence of an engaged needle.
For some applications second end 62 of hub 60 may include flange 63. The dimensions and configuration of second end 62 of hub 60 may be varied to accommodate various insertion sites for an IO device. Hub 60 may be formed with a wide variety of flanges or other configurations compatible with contacting a patient's skin adjacent a desired insertion site.
Passageway 66 may extend from first end 61 through hub 60 to second end 62. Portions of passageway 66 extending from second end 62 may have dimensions selected to be compatible with securely engaging exterior portions of outer penetrator or cannula 70 with hub 60. Second end 72 of cannula 70 may be disposed within passageway 66 between first end 61 and second end 62. First end 71 of cannula 70 may extend from second end 62 of hub 60. Portions of passageway 66 extending from first end 61 of hub 60 may have an enlarged inside diameter to accommodate attachment with various types of fluid connectors.
Cannula or outer penetrator 70 may have longitudinal bore 73 extending from first end 71 to second end 72. Exterior dimensions of trocar or inner penetrator 42 are preferably selected to allow inner penetrator 42 be inserted through outer penetrator 70 with first end 44 of inner penetrator 42 generally aligned with first end 71 of outer penetrator 70 after threads 67 have been engaged with threads 37.
Tip 71 of outer penetrator 70 and/or tip 44 of inner penetrator 42 may be operable to penetrate bone and associated bone marrow. The configuration of tips 71 and 44 may be selected to penetrate a bone, bone marrow and other portions of a patient's body with minimum trauma. For some applications tip 44 of inner penetrator 42 may have a generally trapezoid shape with one or more cutting surfaces.
For some applications tips 71 and 44 may be ground together as a single unit during an associated manufacturing process. Providing a matching fit allows respective tips 71 and 44 to act as a single drilling unit to minimize damage as portions of IO needle set 40 are inserted into a bone and associated bone marrow.
Inner penetrator 42 may sometimes include a longitudinal groove (not expressly shown) that runs along one side of inner penetrator 42 to allow bone chips and/or tissue to exit an insertion site as penetrator assembly 40 is drilled deeper into an associated bone. Outer penetrator 70 and/or inner penetrator 42 may be formed from various materials including, but not limited to, stainless steel, titanium or any other material having suitable strength and durability to penetrate bone and associated bone marrow. The combination of hub 60 with cannula 70 may sometimes be referred to as an “intraosseous needle.” The combination of trocar 42 with cannula 70 may sometimes be referred to as a “penetrator set.”
Second end 62 and particularly flange 63 may be used to stabilize hub 60 after insertion into a selected target area of a patient. Second end 32 of connector 30 may be releasably engaged from first end 61 of hub 60 after insertion of outer penetrator 70 into associated bone marrow. The depth of such insertion may be dependent upon the distance between tip 71 of cannula 70 and second end 62 of hub 60. Various types of tubing and/or conduit may then be engaged with threads 67 formed on the exterior of hub 60 proximate first end or pin end 61.
Annular slot or groove 64 may be formed within second end 62 and sized to receive one end of protective cover or needle cap 80. Slot or groove 64 may be used to releasably engage cover 80 with penetrator assembly 40. For some applications cover 80 may be described as a generally hollow tube having rounded end or closed end 82. Cover 80 may be disposed within annular groove 74 to protect portions of outer penetrator 70 and inner penetrator 42 prior to attachment with a manual driver or a powered driver. Cover 80 may include a plurality of longitudinal ridges 84 formed on the exterior thereof. Longitudinal ridges 84 may cooperate with each other to allow installing and removing cover or needle cap 80 without contaminating portions of an associated penetrator needle or IO device. Cover 80 may be formed from various types of plastics and/or metals.
Container 50 as shown in
Various examples of apparatus and methods which may be used to communicate fluids with an intraosseous device in accordance with teachings of the present disclosure are shown in
For example,
Connector assembly 90 may also include any appropriate features or components selected to facilitate attachment to any suitable connections (e.g., extension tubes) for fluid delivery or monitoring devices. For example, connector assembly 90 may include external threads 94 selected to be compatible with a luer lock or other threaded connection.
Connector assembly 90 may include components intended to allow fluid access to hub 60 when appropriate connectors are present. For example, connector assembly may include plug 96. Plug 96 may be any compressible material (e.g., rubber and/or synthetic rubber). In such embodiments, connector assembly 90 may be configured so that plug 96 is under at least some compression in order to create a liquid seal against an inner surface of connector assembly 90. For example connector assembly 90 may include a Halkey-Roberts luer activated valve.
One having ordinary skill in the art may recognize additional traditional medical equipment that may be compatible with the IO devices described herein. Intraosseous infusion may often require a higher pressure than that normally used for intraosseous infusion. For embodiments such as shown in
As shown in
In some embodiments, such as that shown in
Supporting structure 130 such as shown in
Two examples of an intraosseous device inserted into bone and associated bone marrow along with a supporting structure and attachment mechanism incorporating teachings of the present disclosure are shown in
As discussed in relation to
In some embodiments, such as that shown in
Also as shown in
Depth limiter 150 may include first end 152. Depth limiter 150 may be disposed along the length of IO needle 70 so that a predetermined length of IO needle 70 extends beyond first end 152. First end 152 may be configured to function as a physical stop against the exterior of bone 148 without penetrating into bone marrow 146. In such embodiments, depth limiter 150 may function to limit the penetration of needle 70 into bone marrow 146.
Depth limiter 150 may include second end 154. Second end 154 may be configured to mate with internal features of hub 60 and to fix the location of depth limiter 150 in relation to hub 60. Second end 154 may include any physical characteristic, feature, device and/or component suitable for mating with hub 60. In some embodiments, such as that shown in
An intraosseous device such as hub 60 may be inserted through hollow ring 156. For some applications hub 60 may first be inserted into bone marrow 146. Inside diameter 158 of hollow ring 156 may be selected to be compatible with the dimensions and configuration of second end 62 such that supporting structure 130 may be inserted over or releasably engaged with hub 60 after insertion into bone marrow 146. Alternatively, hollow ring 156 may be formed from material having sufficient flexibility to accommodate expanding to fit over the exterior of hub 60. Hollow ring 156 may have an exterior shape of a cylinder or any other geometric configuration compatible with supporting structure 130. For example, in embodiments such as that shown in
In some embodiments, outer collar 162 may include one or more tubing clips 168. Tubing clips 168 may be any device or structure configured to restrain medical tubing and/or any other material that may be connected to intraosseous device. For example, as shown in
As shown in
Inner collar 160 may also include pawls 172. Pawls 172 may be operable to engage with locking grooves 170 formed on inside of outer collar 162. In such embodiments, locking grooves 170 and pawls 172 may be operable to fix the depth of insertion of inner collar 160 into outer collar 162.
In embodiments including pawls 172, inner collar 160 may comprise a flexible material, such as an elastic polymer or plastic. Inner collar 160 may include notches 169 (clearly shown in
Outer collar 192 may include additional physical features configured to maintain a reduced inner diameter even after the external force is removed. For example, outer collar 192 may include snap-grip 198. Snap-grip 198 may be operable to reduce the diameter of outer collar 192 as snap-grip 198 is squeezed closed. Snap-grip 198 may include any feature operable to restrain the outer collar 192 from increasing the distance between teeth 194 once reduced. Snap-grip 198 may be operable to release outer collar 192 as snap-grip 198 is twisted open.
At the same time, the attachment of luer lock cap 140 to hub 60 pushes inner collar 160 in place in relation to hub 60. Luer lock cap 140 may be configured so as to rotate freely around right angle connector 142. Luer lock cap 140 may be restricted against longitudinal movement by steps 143 included in right angle connector 142. In addition, in embodiments such as those depicted in
In such embodiments, the attachment of luer lock cap 140 may push inner collar 160 downward onto flange 63 on hub 60. Inner collar 160 may include, as discussed in relation to
In alternative embodiments, outer collar 162 may not include grooves 170. In such embodiments, pawls 172 may be configured to extend outward and operate as a friction lock with inner diameter 163 of outer collar 162. In such embodiments, inner diameter 163 may include any feature (e.g., a rough surface) such that inner diameter 163 and pawls 172 may be operable to form an effective lock against longitudinal movement between inner collar 160 and outer collar 162.
A person having ordinary skill in the art will recognize that the longitudinal position of inner collar 160 in relations to outer collar 162 may be purposefully varied to accommodate various applications. For example, if the target insertion site for the IO device includes bone with a small and/or soft cortex, the bone itself may not provide much lateral support for hub 60 once inserted. Second end 62 of hub 60 may contact skin 145 in isolated points or not at all. In such cases, outer collar 162 may intentionally extend downward well beyond inner collar 160 in order to provide significant extra stabilization, especially when used at insertion sites where the skin soft tissue layer is relatively thin. Outer collar 162 may include bottom face 174. Bottom face 174 may include any treatment intended to improve contact between outer collar 162 and target insertion site. For example, bottom face 174 may include any biocompatible adhesive material configured to adhere bottom face 174 to skin 145. In embodiments including depth limiter 150, depth limiter 150 may restrict the insertion depth of cannula 70 to the extent that hub 60 does not contact skin 145. In such embodiments, outer collar 162 may provide extra stabilization when extending downward beyond hub 60 and/or inner collar 160.
Although the present disclosure and its advantages have been described in relation to intraosseous devices, it should be clear to a person having ordinary skill in the art that these teachings can be applied to support a variety of medical devices in relation to a patient. For example, embodiments of the present disclosure might be utilized to support any intravenous connection or device, a central line, an endotracheal tube, a chest tube, a catheter, dialysis tubing and/or any other device intended to make a fluid connection to one or more systems of the patient.
Examples of acute and chronic conditions which may be treated using intraosseous devices and procedures incorporating teachings of the present disclosure include, but are not limited to, the following:
Anaphylaxis (epinephrine, steroids, antihistamines, fluids, and life support);
Arrhythmia (anti-arrhythmics, electrolyte balance, life support);
Burns (fluid replacement, antibiotics, morphine for pain control);
Cardiac arrest (epinephrine, atropine, amiodarone, calcium, xylocalne, magnesium);
Congestive heart failure (life support, diuretics, morphine, nitroglycerin);
Dehydration (emergency port for life support, antibiotics, blood, electrolytes);
Diabetic Ketoacidosis (life support, electrolyte control, fluid replacement);
Dialysis (emergency port for life support, antibiotics, blood, electrolytes);
Drug overdose (naloxone, life support, electrolyte correction);
Emphysema (life support, beta adrenergics, steroids);
Hemophiliacs (life support, blood, fibrin products, analgesics);
Osteomyelitis (antibiotics directly into the site of infection, analgesics);
Pediatric applications (shock, dehydration, nutrition, electrolyte correction);
Seizures (anti-seizure medications, life support, fluid balance);
Shock (life support fluids, pressor agents, antibiotics, steroids);
Sickle cell crisis (fluid, morphine for pain, blood, antibiotics);
Trauma (emergency port for life support fluids, antibiotics, blood, electrolytes);
Although the present disclosure and its advantages have been described in detail, it should be understood that various changes, substitutions and alternations can be made herein without departing from the spirit and scope of the disclosure as defined by the following claims.
This application is a divisional application of U.S. patent application Ser. No. 14/643,839, filed Mar. 10, 2015, which is a continuation application of U.S. patent application Ser. No. 11/619,390, filed Jan. 3, 2007, now U.S. Pat. No. 8,974,410, which claims the benefit of U.S. Provisional Patent Application Ser. No. 60/863,521, filed Oct. 30, 2006. The contents of each of these applications are incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
2223219 | Bernat et al. | Nov 1940 | A |
2317648 | Siqveland et al. | Apr 1943 | A |
2419045 | Whittaker et al. | Apr 1947 | A |
2773501 | Young et al. | Dec 1956 | A |
3104448 | Morrow et al. | Sep 1963 | A |
3120845 | Horner et al. | Feb 1964 | A |
3173417 | Horner et al. | Mar 1965 | A |
3175554 | Stewart et al. | Mar 1965 | A |
3507276 | Burgess et al. | Apr 1970 | A |
3543966 | Ryan et al. | Dec 1970 | A |
3815605 | Schmidt et al. | Jun 1974 | A |
3835860 | Garretson | Sep 1974 | A |
3893445 | Hofsess | Jul 1975 | A |
3991765 | Cohen | Nov 1976 | A |
4021920 | Kirschner et al. | May 1977 | A |
4099518 | Baylis et al. | Jul 1978 | A |
4124026 | Berner et al. | Nov 1978 | A |
4142517 | Stavropoulos et al. | Mar 1979 | A |
4170993 | Alvarez | Oct 1979 | A |
4185619 | Reiss | Jan 1980 | A |
4194505 | Schmitz | Mar 1980 | A |
4258722 | Sessions et al. | Mar 1981 | A |
4262676 | Jamshidi | Apr 1981 | A |
4306570 | Matthews | Dec 1981 | A |
4333459 | Becker | Jun 1982 | A |
4381777 | Garnier | May 1983 | A |
4441563 | Walton, II | Apr 1984 | A |
4469109 | Mehl | Sep 1984 | A |
4484577 | Sackner et al. | Nov 1984 | A |
4543966 | Islam et al. | Oct 1985 | A |
4553539 | Morris | Nov 1985 | A |
4605011 | Naslund | Aug 1986 | A |
4620539 | Andrews et al. | Nov 1986 | A |
4646731 | Brower | Mar 1987 | A |
4654492 | Koerner et al. | Mar 1987 | A |
4655226 | Lee | Apr 1987 | A |
4659329 | Annis | Apr 1987 | A |
4692073 | Martindell | Sep 1987 | A |
4713061 | Tarello et al. | Dec 1987 | A |
4716901 | Jackson et al. | Jan 1988 | A |
4723945 | Theiling | Feb 1988 | A |
4758225 | Cox et al. | Jul 1988 | A |
4772261 | Von Hoff et al. | Sep 1988 | A |
4787893 | Villette | Nov 1988 | A |
4793363 | Ausherman et al. | Dec 1988 | A |
4838282 | Strasser et al. | Jun 1989 | A |
4867158 | Sugg | Sep 1989 | A |
4919146 | Rhinehart et al. | Apr 1990 | A |
4921013 | Spalink et al. | May 1990 | A |
4935010 | Cox et al. | Jun 1990 | A |
4940459 | Noce | Jul 1990 | A |
4944677 | Alexandre | Jul 1990 | A |
4969870 | Kramer et al. | Nov 1990 | A |
4986279 | O'Neill | Jan 1991 | A |
5002546 | Romano | Mar 1991 | A |
5025797 | Baran | Jun 1991 | A |
5036860 | Leigh et al. | Aug 1991 | A |
5057085 | Kopans | Oct 1991 | A |
5074311 | Hasson | Dec 1991 | A |
5116324 | Brierley et al. | May 1992 | A |
5120312 | Wigness et al. | Jun 1992 | A |
5122114 | Miller et al. | Jun 1992 | A |
5133359 | Kedem | Jul 1992 | A |
5137518 | Mersch | Aug 1992 | A |
5139500 | Schwartz | Aug 1992 | A |
RE34056 | Lindgren et al. | Sep 1992 | E |
5172701 | Leigh | Dec 1992 | A |
5172702 | Leigh et al. | Dec 1992 | A |
5176643 | Kramer et al. | Jan 1993 | A |
5195985 | Hall | Mar 1993 | A |
5203056 | Funk et al. | Apr 1993 | A |
5207697 | Carusillo et al. | May 1993 | A |
5249583 | Mallaby | Oct 1993 | A |
5257632 | Turkel et al. | Nov 1993 | A |
5269785 | Bonutti | Dec 1993 | A |
5279306 | Mehl | Jan 1994 | A |
5312364 | Jacobs | May 1994 | A |
5312408 | Brown | May 1994 | A |
5324300 | Elias et al. | Jun 1994 | A |
5332398 | Miller et al. | Jul 1994 | A |
5333790 | Christopher | Aug 1994 | A |
5341823 | Manosalva et al. | Aug 1994 | A |
5348022 | Leigh et al. | Sep 1994 | A |
5357974 | Baldridge | Oct 1994 | A |
5368046 | Scarfone et al. | Nov 1994 | A |
5372583 | Roberts et al. | Dec 1994 | A |
5383859 | Sewell, Jr. | Jan 1995 | A |
5385553 | Hart et al. | Jan 1995 | A |
5400798 | Baran | Mar 1995 | A |
5405362 | Kramer et al. | Apr 1995 | A |
5423824 | Akerfeldt et al. | Jun 1995 | A |
5431655 | Melker et al. | Jul 1995 | A |
5451210 | Kramer et al. | Sep 1995 | A |
5484442 | Melker et al. | Jan 1996 | A |
D369858 | Baker et al. | May 1996 | S |
5526821 | Jamshidi | Jun 1996 | A |
5529580 | Kusunoki et al. | Jun 1996 | A |
5554154 | Rosenberg | Sep 1996 | A |
5556399 | Huebner | Sep 1996 | A |
5558737 | Brown et al. | Sep 1996 | A |
5586847 | Mattern, Jr. et al. | Dec 1996 | A |
5591188 | Waisman | Jan 1997 | A |
5595186 | Rubinstein et al. | Jan 1997 | A |
5601559 | Melker et al. | Feb 1997 | A |
5632747 | Scarborough et al. | May 1997 | A |
5713368 | Leigh | Feb 1998 | A |
5724873 | Hillinger | Mar 1998 | A |
5733262 | Paul | Mar 1998 | A |
5752923 | Terwilliger | May 1998 | A |
5762639 | Gibbs | Jun 1998 | A |
5769086 | Ritchart et al. | Jun 1998 | A |
5779708 | Wu | Jul 1998 | A |
5800389 | Burney et al. | Sep 1998 | A |
5807277 | Swaim | Sep 1998 | A |
5810826 | Akerfeldt et al. | Sep 1998 | A |
5817052 | Johnson et al. | Oct 1998 | A |
5823970 | Terwilliger | Oct 1998 | A |
D403405 | Terwilliger | Dec 1998 | S |
5858005 | Kriesel | Jan 1999 | A |
5868711 | Kramer et al. | Feb 1999 | A |
5873510 | Hirai et al. | Feb 1999 | A |
5885226 | Rubinstein et al. | Mar 1999 | A |
5891085 | Lilley et al. | Apr 1999 | A |
5911701 | Miller et al. | Jun 1999 | A |
5911708 | Teirstein | Jun 1999 | A |
5916229 | Evans | Jun 1999 | A |
5919172 | Golba, Jr. | Jul 1999 | A |
5924864 | Loge et al. | Jul 1999 | A |
5927976 | Wu | Jul 1999 | A |
5928238 | Scarborough et al. | Jul 1999 | A |
5941706 | Ura | Aug 1999 | A |
5941851 | Coffey et al. | Aug 1999 | A |
5960797 | Kramer et al. | Oct 1999 | A |
5980545 | Pacala et al. | Nov 1999 | A |
5993417 | Yerfino et al. | Nov 1999 | A |
5993454 | Longo | Nov 1999 | A |
6007496 | Brannon | Dec 1999 | A |
6017348 | Hart et al. | Jan 2000 | A |
6018094 | Fox | Jan 2000 | A |
6022324 | Skinner | Feb 2000 | A |
6027458 | Janssens | Feb 2000 | A |
6033369 | Goldenberg | Mar 2000 | A |
6033411 | Preissman | Mar 2000 | A |
6063037 | Mittermeier et al. | May 2000 | A |
6080115 | Rubinstein | Jun 2000 | A |
6083176 | Terwilliger | Jul 2000 | A |
6086544 | Hibner et al. | Jul 2000 | A |
6096042 | Herbert | Aug 2000 | A |
6102915 | Bresler et al. | Aug 2000 | A |
6106484 | Terwilliger | Aug 2000 | A |
6110128 | Andelin et al. | Aug 2000 | A |
6110129 | Terwilliger | Aug 2000 | A |
6110174 | Nichter | Aug 2000 | A |
6120462 | Hibner et al. | Sep 2000 | A |
6135769 | Kwan | Oct 2000 | A |
6159163 | Strauss et al. | Dec 2000 | A |
6162203 | Haaga | Dec 2000 | A |
6183442 | Athanasiou et al. | Feb 2001 | B1 |
6210376 | Grayson | Apr 2001 | B1 |
6217561 | Gibbs | Apr 2001 | B1 |
6221029 | Mathis et al. | Apr 2001 | B1 |
6228049 | Schroeder et al. | May 2001 | B1 |
6228088 | Miller et al. | May 2001 | B1 |
6238355 | Daum | May 2001 | B1 |
6247928 | Meller et al. | Jun 2001 | B1 |
6248110 | Reiley et al. | Jun 2001 | B1 |
6257351 | Ark et al. | Jul 2001 | B1 |
6273715 | Meller et al. | Aug 2001 | B1 |
6273862 | Privitera et al. | Aug 2001 | B1 |
6283925 | Terwilliger | Sep 2001 | B1 |
6283970 | Lubinus | Sep 2001 | B1 |
6287114 | Meller et al. | Sep 2001 | B1 |
6302852 | Fleming, III et al. | Oct 2001 | B1 |
6309358 | Okubo | Oct 2001 | B1 |
6312394 | Fleming, III | Nov 2001 | B1 |
6315737 | Skinner | Nov 2001 | B1 |
6325806 | Fox | Dec 2001 | B1 |
6328701 | Terwilliger | Dec 2001 | B1 |
6328744 | Harari et al. | Dec 2001 | B1 |
6358252 | Shapira | Mar 2002 | B1 |
6402701 | Kaplan et al. | Jun 2002 | B1 |
6419490 | Kitchings Weathers, Jr. | Jul 2002 | B1 |
6425888 | Embleton et al. | Jul 2002 | B1 |
6428487 | Burdorff et al. | Aug 2002 | B1 |
6443910 | Krueger et al. | Sep 2002 | B1 |
6468248 | Gibbs | Oct 2002 | B2 |
6478751 | Krueger et al. | Nov 2002 | B1 |
6488636 | Bryan et al. | Dec 2002 | B2 |
6523698 | Dennehey et al. | Feb 2003 | B1 |
6527736 | Attinger et al. | Mar 2003 | B1 |
6527778 | Athanasiou et al. | Mar 2003 | B2 |
6540694 | Van Bladel et al. | Apr 2003 | B1 |
6547511 | Adams | Apr 2003 | B1 |
6547561 | Meller et al. | Apr 2003 | B2 |
6554779 | Viola et al. | Apr 2003 | B2 |
6555212 | Boiocchi et al. | Apr 2003 | B2 |
6582399 | Smith et al. | Jun 2003 | B1 |
6585622 | Shum et al. | Jul 2003 | B1 |
6595911 | LoVuolo | Jul 2003 | B2 |
6595979 | Epstein et al. | Jul 2003 | B1 |
6613054 | Scribner et al. | Sep 2003 | B2 |
6616632 | Sharp et al. | Sep 2003 | B2 |
6620111 | Stephens et al. | Sep 2003 | B2 |
6626848 | Neuenfeldt | Sep 2003 | B2 |
6626887 | Wu | Sep 2003 | B1 |
6638235 | Miller et al. | Oct 2003 | B2 |
6656133 | Voegele et al. | Dec 2003 | B2 |
6689072 | Kaplan et al. | Feb 2004 | B2 |
6702760 | Krause et al. | Mar 2004 | B2 |
6702761 | Damadian et al. | Mar 2004 | B1 |
6706016 | Cory et al. | Mar 2004 | B2 |
6716192 | Orosz, Jr. | Apr 2004 | B1 |
6716215 | David et al. | Apr 2004 | B1 |
6716216 | Boucher et al. | Apr 2004 | B1 |
6730043 | Krueger et al. | May 2004 | B2 |
6730044 | Stephens et al. | May 2004 | B2 |
6749576 | Bauer | Jun 2004 | B2 |
6752768 | Burdorff et al. | Jun 2004 | B2 |
6752816 | Culp et al. | Jun 2004 | B2 |
6758824 | Miller et al. | Jul 2004 | B1 |
6761726 | Findlay et al. | Jul 2004 | B1 |
6796957 | Carpenter et al. | Sep 2004 | B2 |
6846314 | Shapira | Jan 2005 | B2 |
6849051 | Sramek et al. | Feb 2005 | B2 |
6855148 | Foley et al. | Feb 2005 | B2 |
6860860 | Viola | Mar 2005 | B2 |
6875183 | Cervi | Apr 2005 | B2 |
6875219 | Arramon et al. | Apr 2005 | B2 |
6884245 | Spranza, III | Apr 2005 | B2 |
6887209 | Kadziauskas et al. | May 2005 | B2 |
6890308 | Islam | May 2005 | B2 |
6905486 | Gibbs | Jun 2005 | B2 |
6930461 | Rutkowski | Aug 2005 | B2 |
6942669 | Kurc | Sep 2005 | B2 |
6969373 | Schwartz et al. | Nov 2005 | B2 |
7008381 | Janssens | Mar 2006 | B2 |
7008383 | Damadian et al. | Mar 2006 | B1 |
7008394 | Geise et al. | Mar 2006 | B2 |
7025732 | Thompson et al. | Apr 2006 | B2 |
7063672 | Schramm | Jun 2006 | B2 |
7137985 | Jahng | Nov 2006 | B2 |
7207949 | Miles et al. | Apr 2007 | B2 |
7226450 | Athanasiou et al. | Jun 2007 | B2 |
7229401 | Kindlein | Jun 2007 | B2 |
7670328 | Miller | Mar 2010 | B2 |
7699850 | Miller | Apr 2010 | B2 |
7811260 | Miller et al. | Oct 2010 | B2 |
7815642 | Miller | Oct 2010 | B2 |
7850620 | Miller et al. | Dec 2010 | B2 |
7951089 | Miller | May 2011 | B2 |
8038664 | Miller et al. | Oct 2011 | B2 |
8419683 | Miller et al. | Apr 2013 | B2 |
8480632 | Miller et al. | Jul 2013 | B2 |
8506568 | Miller | Aug 2013 | B2 |
8641715 | Miller | Feb 2014 | B2 |
8656929 | Miller et al. | Feb 2014 | B2 |
8668698 | Miller et al. | Mar 2014 | B2 |
8684978 | Miller et al. | Apr 2014 | B2 |
8690791 | Miller | Apr 2014 | B2 |
8715287 | Miller | May 2014 | B2 |
8812101 | Miller et al. | Aug 2014 | B2 |
8974410 | Miller | Mar 2015 | B2 |
10258783 | Miller | Apr 2019 | B2 |
20010014439 | Meller et al. | Aug 2001 | A1 |
20010047183 | Privitera et al. | Nov 2001 | A1 |
20010053888 | Athanasiou et al. | Dec 2001 | A1 |
20020020715 | Gueret | Feb 2002 | A1 |
20020042581 | Cervi | Apr 2002 | A1 |
20020055713 | Gibbs | May 2002 | A1 |
20020120212 | Ritchart et al. | Aug 2002 | A1 |
20020138021 | Pflueger | Sep 2002 | A1 |
20030028146 | Aves | Feb 2003 | A1 |
20030032939 | Gibbs | Feb 2003 | A1 |
20030036747 | Ie et al. | Feb 2003 | A1 |
20030050574 | Krueger | Mar 2003 | A1 |
20030114858 | Athanasiou et al. | Jun 2003 | A1 |
20030125639 | Fisher et al. | Jul 2003 | A1 |
20030153842 | Lamoureux et al. | Aug 2003 | A1 |
20030191414 | Reiley et al. | Oct 2003 | A1 |
20030195436 | Van Bladel et al. | Oct 2003 | A1 |
20030195524 | Barner | Oct 2003 | A1 |
20030199787 | Schwindt | Oct 2003 | A1 |
20030216667 | Viola | Nov 2003 | A1 |
20030225344 | Miller | Dec 2003 | A1 |
20030225364 | Kraft et al. | Dec 2003 | A1 |
20030225411 | Miller | Dec 2003 | A1 |
20040019297 | Angel | Jan 2004 | A1 |
20040019299 | Ritchart et al. | Jan 2004 | A1 |
20040034280 | Privitera et al. | Feb 2004 | A1 |
20040049128 | Miller et al. | Mar 2004 | A1 |
20040064136 | Papineau et al. | Apr 2004 | A1 |
20040092946 | Bagga et al. | May 2004 | A1 |
20040153003 | Cicenas et al. | Aug 2004 | A1 |
20040158172 | Hancock | Aug 2004 | A1 |
20040158173 | Voegele et al. | Aug 2004 | A1 |
20040162505 | Kaplan et al. | Aug 2004 | A1 |
20040191897 | Muschler | Sep 2004 | A1 |
20040210161 | Burdorff et al. | Oct 2004 | A1 |
20040215102 | Ikehara et al. | Oct 2004 | A1 |
20040220497 | Findlay et al. | Nov 2004 | A1 |
20050027210 | Miller | Feb 2005 | A1 |
20050040060 | Andersen et al. | Feb 2005 | A1 |
20050075581 | Schwindt | Apr 2005 | A1 |
20050085838 | Thompson et al. | Apr 2005 | A1 |
20050101880 | Cicenas et al. | May 2005 | A1 |
20050113716 | Mueller, Jr. et al. | May 2005 | A1 |
20050124915 | Eggers et al. | Jun 2005 | A1 |
20050131345 | Miller | Jun 2005 | A1 |
20050148940 | Miller | Jul 2005 | A1 |
20050165328 | Heske et al. | Jul 2005 | A1 |
20050165403 | Miller | Jul 2005 | A1 |
20050165404 | Miller | Jul 2005 | A1 |
20050171504 | Miller | Aug 2005 | A1 |
20050182394 | Spero et al. | Aug 2005 | A1 |
20050200087 | Vasudeva et al. | Sep 2005 | A1 |
20050203439 | Heske et al. | Sep 2005 | A1 |
20050209530 | Pflueger | Sep 2005 | A1 |
20050215921 | Hibner et al. | Sep 2005 | A1 |
20050228309 | Fisher et al. | Oct 2005 | A1 |
20050261693 | Miller | Nov 2005 | A1 |
20050267144 | Mandrea | Dec 2005 | A1 |
20060011506 | Riley | Jan 2006 | A1 |
20060015066 | Turieo et al. | Jan 2006 | A1 |
20060036212 | Miller | Feb 2006 | A1 |
20060043118 | Law et al. | Mar 2006 | A1 |
20060052790 | Miller | Mar 2006 | A1 |
20060074345 | Hibner | Apr 2006 | A1 |
20060079774 | Anderson | Apr 2006 | A1 |
20060089565 | Schramm | Apr 2006 | A1 |
20060122535 | Daum | Jun 2006 | A1 |
20060129082 | Rozga | Jun 2006 | A1 |
20060144548 | Beckman et al. | Jul 2006 | A1 |
20060149163 | Hibner et al. | Jul 2006 | A1 |
20060167377 | Ritchart et al. | Jul 2006 | A1 |
20060167378 | Miller | Jul 2006 | A1 |
20060167379 | Miller | Jul 2006 | A1 |
20060184063 | Miller | Aug 2006 | A1 |
20060189940 | Kirsch | Aug 2006 | A1 |
20070016100 | Miller | Jan 2007 | A1 |
20070049945 | Miller | Mar 2007 | A1 |
20070149920 | Michels et al. | Jun 2007 | A1 |
20070213735 | Saadat et al. | Sep 2007 | A1 |
20070270775 | Miller et al. | Nov 2007 | A1 |
20080015467 | Miller | Jan 2008 | A1 |
20080015468 | Miller | Jan 2008 | A1 |
20080045857 | Miller et al. | Feb 2008 | A1 |
20080045860 | Miller et al. | Feb 2008 | A1 |
20080045861 | Miller et al. | Feb 2008 | A1 |
20080045965 | Miller et al. | Feb 2008 | A1 |
20080119572 | Owens et al. | May 2008 | A1 |
20080140014 | Miller et al. | Jun 2008 | A1 |
20080177200 | Ikehara et al. | Jul 2008 | A1 |
20080215056 | Miller et al. | Sep 2008 | A1 |
20080221580 | Miller et al. | Sep 2008 | A1 |
20090232755 | Baumann | Sep 2009 | A1 |
20110082387 | Miller et al. | Apr 2011 | A1 |
20110306841 | Lozman et al. | Dec 2011 | A1 |
Number | Date | Country |
---|---|---|
2138842 | Jun 1996 | CA |
2454600 | Feb 2003 | CA |
2664675 | Dec 2004 | CN |
10057931 | Aug 2002 | DE |
0517000 | Dec 1992 | EP |
0807412 | Nov 1997 | EP |
1314452 | May 2003 | EP |
1421907 | May 2004 | EP |
853349 | Mar 1940 | FR |
2457105 | Dec 1980 | FR |
2516386 | May 1983 | FR |
2130890 | Jun 1984 | GB |
1052433 | Jun 1984 | JP |
9307819 | Apr 1993 | WO |
9631164 | Oct 1996 | WO |
9806337 | Feb 1998 | WO |
9852638 | Nov 1998 | WO |
9918866 | Apr 1999 | WO |
9952444 | Oct 1999 | WO |
0009024 | Feb 2000 | WO |
0056220 | Sep 2000 | WO |
0178590 | Oct 2001 | WO |
0241792 | May 2002 | WO |
02096497 | Dec 2002 | WO |
03015637 | Feb 2003 | WO |
2005072625 | Aug 2005 | WO |
2005110259 | Nov 2005 | WO |
2005112800 | Dec 2005 | WO |
2008033874 | Mar 2008 | WO |
2008081438 | Jul 2008 | WO |
2011030573 | Mar 2011 | WO |
2011123703 | Oct 2011 | WO |
Entry |
---|
Astrom, K.G., “Automatic Biopsy Instruments Used Through a Coaxial Bone Biopsy System with an Eccentric Drill Tip,” Acta Radiologica, vol. 36, pp. 237-242, 1995 [Cited in related U.S. Appl. No. 11/619,390]. |
Astrom, K. Gunnar, “CT-guided Transstemal Core Biopsy of Anterior Mediastinal Masses,” Radiology, vol. 199, pp. 564-567, 1996 [Cited in related U.S. Appl. No. 11/619,390]. |
Pediatric Emergency, Intraosseous Infusion for Administration of Fluids and Drugs, www.cookgroup.com, 1 pg, 2000 [Cited in related U.S. Appl. No. 11/619,390]. |
Michael Trotty, “Technology (A Special Report)—The Wall Street Journal 2008 Technology Innovation Awards This years winners include: an IV alternative, a better way to make solar panels, a cheap, fuel efficient car and a better way to see in the dark”, The Wall Street Journal, Factiva, 5 pages, 2008 [Cited in related U.S. Appl. No. 11/619,390]. |
Buckley et al., “CT-guided bone biopsy: Initial experience with commercially available hand held Black and Decker drill,” European Journal of Radiology, vol. 61, pp. 176-180, 2007 [Cited in related U.S. Appl. No. 11/619,390]. |
Hakan et al., “CT-guided Bone Biopsy Performed by Means of Coaxial Biopsy System with an Eccentric Drill,” Radiology, pp. 549-552, Aug. 1993 [Cited in related U.S. Appl. No. 11/619,390]. |
BioAccess.com, “Single Use Small Bone Power Tool—How It Works,” 1 pg.,Printed Jun. 9, 2008 [Cited in related U.S. Appl. No. 11/619,390]. |
Liakat A. Parapia, “Trepanning or trephines: a history of bone marrow biopsy,” British Journal of Haematology, pp. 14-19, 2007 [Cited in related U.S. Appl. No. 11/619,390]. |
Gunal et al., “Compartment Syndrome After Intraosseous Infusion: An Experimental Study in Dogs,” Journal of Pediatric Surgery, vol. 31, No. 11, pp. 1491-1493, Nov. 1996 [Cited in related U.S. Appl. No. 11/619,390]. |
“Proven reliability for quality bone marrow samples,” Special Procedures, Cardinal Health, 6 pages, 2003 [Cited in related U.S. Appl. No. 11/619,390]. |
F.A.S.T. 1 Intraosseous Infusion System with Depth-Control Mechanism Brochure, 6 pages, 2000 [Cited in related U.S. Appl. No. 11/619,390]. |
Pediatrics, Official Journal of the American Academy of Pediatrics, Pediatrics, 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care of Pediatric and Neonatal Patients: Pediatric Advanced Life Support, Downloaded from www.pediatrics.org. pp. e1005-e1028, Feb. 21, 2007 [Cited in related U.S. Appl. No. 11/619,390]. |
Cummins et al., “ACLS—Principles and Practice,” ACLS—The Reference Textbook, American Heart Association, pp. 214-218, 2003 [Cited in related U.S. Appl. No. 11/619,390]. |
Riley et al., “A Pathologist's Perspective on Bone Marrow Aspiration Biopsy: I. Performing a Bone Marrow Examination,” Journal of Clinical Laboratory Analysis 18, pp. 70-90, 2004 [Cited in related U.S. Appl. No. 11/619,390]. |
Australian Exam Report on Patent Application No. 2003240970, 2 pages, dated Oct. 15, 2007. |
Chinese Office Action with English translation; Application No. 200780000585.5; pp. 15, dated Nov. 19, 2010. |
Communication Pursuant to Article 94(3) EPC in European Application No. 05712091.7 dated Apr. 8, 2008. |
Communication relating to the results of the partial International Search Report for dated PCT/US2005/002484, 6 pages dated May 19, 2005. |
International PCT Search Report and Written Opinion PCT /US2005/002484, 15 pages, dated Jul. 22, 2005. |
International PCT Search Report and Written Opinion PCT/US2004/037753, 16 pages, dated Jul. 8, 2005. |
International PCT Search Report PCT/US03/17167, 8 pages, dated Sep. 16, 2003. |
International PCT Search Report PCT/US03/17203, 8 pages, dated Sep. 16, 2003. |
International PCT Search Report PCT/US2004/037753, 6 pages, dated Apr. 19, 2005. |
International Prelimarinary Report on Patentability in International Application No. PCT/US2012/046294 dated Jan. 23, 2014. |
International Preliminary Report on Patentability in International Application No. PCT/US2005/002484 dated Aug. 3, 2006. |
International Preliminary Reporton Patentability for international application PCT/US2006/025201, dated Feb. 7, 2008. |
International Preliminary Report on Patentability for international application PCT/US2007/072202. dated Jan. 15, 2009. |
International Preliminary Report on Patentability in International Application No. PCT/US/2007/072209, dated May 14, 2009. |
International Preliminary Reporton Patentability in International Application No. PCT/US2007/072217 dated Feb. 12, 2009. |
International Search Report and Written Opinion for international application PCT/US2007/078203, dated May 13, 2008. |
International Search Report and Written Opinion for international application PCT/US2007/078204, dated May 15, 2008. |
International Search Report and Written Opinion for international application PCT/US2007/078205, dated Sep. 11, 2007. |
International Search Report and Written Opinion for international application PCT/US2007/078207, dated Apr. 7, 2008. |
International Search Report and Written Opinion for international application PCT/US2008/0500346. dated May 22, 2008. |
International Search Report and Written Opinion for International Patent Application No. PCT/US2007/072202, dated Mar. 25, 2008. |
International Search Report and Written Opinion issued in PCT Application No. PCT/US2007/072209 dated Apr. 25, 2008. |
International Search Report and Written Opinion issued in PCT Application No. PCT/US2007/072217 dated Mar. 31, 2008. |
International Search Report and Written Opinion, PCT/US08/52943 8 pages, dated Sep. 26, 2008. |
International Search Report in International Application No. PCT/US2012/046294 dated Jan. 24, 2013. |
Non-Final Office Action, U.S. Appl. No. 10/449,476, 8 pages, dated Oct. 29, 2008. |
Notice of Allowance in U.S. Appl. No. 11/620,927 dated Jun. 3, 2014. |
Notice of Allowance in U.S. Appl. No. 12/407,651 dated Jun. 11, 2014. |
Notification of the First Chinese Office Action, Application No. 200580003261.8, 3 pages, dated Mar. 21, 2008. |
Office Action for European application 03731475.4, dated Oct. 11, 2007. |
Office Action for U.S. Appl. No. 11/427,501, dated Aug. 7, 2008. |
Office Action in Chinese Patent Application No. 200780000585.5 dated Feb. 29, 2012. |
Office Action in Chinese Patent Application No. 200780000585.5 dated Jan. 21, 2013. |
Office Action in Chinese Patent Application No. 200780000585.5 dated Sep. 26, 2012. |
Office Action in European Application No. 03756317.8 dated Dec. 28, 2006. |
Office Action in European Application No. 08158699.2 dated Nov. 4, 2008. |
Office Action in European Application No. 1281109035 dated Feb. 20, 2014. |
Office Action in Taiwanese Patent Application No. 096140082 dated Jun. 5, 2014. |
Office Action in Taiwanese Patent Application No. 096140082 dated Oct. 30, 2013. |
Office Action in U.S. Appl. No. 13/546,894 dated Dec. 30, 2013. |
Office Action in U.S. Appl. No. 13/546,894 dated Jul. 18, 2014. |
Office Communication issued in European Patent Application No. 09150973.7, dated Dec. 22, 2011. |
Office Communication issued in Taiwanese Patent Application No. 096140082, dated Mar. 27, 2013. |
PCT Invitation to Pay Additional Fees in International Application No. PCT/US2007/072209 dated Dec. 3, 2007. |
Rejection Decision in Chinese Patent Application No. 200780000585.5 dated Apr. 27, 2013. |
Search Report and Written Opinion in International Application No. PCT/US2006/025201 dated Jan. 29, 2007. |
Search Report in European Application No. 08158699.2 dated Aug. 2008. |
Number | Date | Country | |
---|---|---|---|
20190224464 A1 | Jul 2019 | US |
Number | Date | Country | |
---|---|---|---|
60863521 | Oct 2006 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14643839 | Mar 2015 | US |
Child | 16372056 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11619390 | Jan 2007 | US |
Child | 14643839 | US |